BCG overexpressing an endogenous STING agonist provides enhanced protection against pulmonary tuberculosis

Ruchi Jain Dey, Bappaditya Dey, Alok Kumar Singh, Monali Praharaj, William Bishai

Research output: Contribution to journalArticlepeer-review

Abstract

Stimulator of interferon genes (STING) has emerged as a key signaling receptor that induces proinflammatory cytokines, and small molecule STING agonists are being developed as anticancer and antiviral agents. Here we report a strategy of delivering a STING agonist from within live BCG. We generated a recombinant BCG (BCG-disA-OE) that overexpresses the endogenous mycobacterial diadenylate cyclase gene and releases high levels of the STING agonist c-di-AMP. In macrophages BCG-disA-OE elicited statistically significantly stronger TNF-α, IL-6, IL-1β, IRF3, and IFN-β levels than BCG-WT. In a 24-week guinea pig vaccination-Mtb challenge model, BCG-disA-OE reduced lung weights, pathology scores, and Mtb CFU counts in lungs by 28% (p<0.05), 34%, and 2.0 log10 CFU units (p < 0.5) compared with BCG-WT, respectively. Overproduction of the STING agonist c-di-AMP significantly enhanced the protective efficacy of BCG against pulmonary and extrapulmonary tuberculosis. Our findings support the development of BCG-vectored STING agonists as a TB vaccine strategy.

Original languageEnglish (US)
JournalUnknown Journal
DOIs
StatePublished - Jul 9 2018

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • Immunology and Microbiology(all)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'BCG overexpressing an endogenous STING agonist provides enhanced protection against pulmonary tuberculosis'. Together they form a unique fingerprint.

Cite this